Skip to Main Content

Amid ongoing concern about the use of patient assistance programs by the pharmaceutical industry, two lawmakers want the Inspector General of the Department of Health and Human Services to update its oversight and require more disclosure from the foundations about their operations.

In arguing their case, the lawmakers maintained that some drug makers game the system by finding ways to boost sales of their own medicines while also benefiting from tax breaks. At the same time, they contended that programs favor expensive brand-name medicines over lower-cost generics and sometimes fail to help patients with the most need.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • An astute but troubling observation -“97% — required insurance coverage for eligibility” One would think the uninsured would require the most assistance? (Assuming they have fallen through the cracks rather than willfully being uninsured as a protest against the ACA.)

Comments are closed.